AGC Biologics Expands Biologics Capacity
The contract development and manufacturing organization has expanded biologics capacity at its facility in Berkeley, CA.
Contract development and manufacturing organization AGC Biologics announced on March 6, 2018 that it is adding a 2000-L single-use bioreactor to its Berkeley, CA, facility to support its biologics capacity.
According to the company, its Berkeley facility, one of six facilities worldwide, has tripled in capacity over the past three years. The facility uses both single-use and stainless-steel bioreactors for cell culture manufacturing in scales from 100–3000L. In addition to cGMP manufacturing, the facility provides cell bank manufacturing and storage.
AGC Biologics is a recent integration of Asahi Glass Company (AGC) Bioscience, a glass and chemical producer under AGC, Biomeva GmbH, a contract manufacturing organization, and CMC Biologics, a contract biologics manufacturer, which was announced in January 2018. The newly-branded company specializes in customized services for the scale-up and cGMP manufacture of protein-based therapeutics.
Source: AGC Biologics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.
